SEARCH

SEARCH BY CITATION

References

  • 1
    Lindahl U, Li JP. Interactions between heparan sulfate and proteins-design and functional implications. Int Rev Cell Mol Biol 2009; 276: 1059.
  • 2
    Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 68898.
  • 3
    Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed Engl 2002; 41: 391412.
  • 4
    Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. Annu Rev Med 2010; 61: 7790.
  • 5
    Ziporen L, Li ZQ, Park KS, Sabnekar P, Liu WY, Arepally G, Shoenfeld Y, KieberEmmons T, Cines DB, Poncz M. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 1998; 92: 32509.
  • 6
    Li ZQ, Liu W, Park KS, Sachais BS, Arepally GM, Cines DB, Poncz M. Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood 2002; 99: 12306.
  • 7
    Thompson CA. FDA approves first generic enoxaparin product. Am J Health Syst Pharm 2010; 67: 1486, 1488.
  • 8
    Jeske WP, Walenga JM, Hoppensteadt DA, Vandenberg C, Brubaker A, Adiguzel C, Bakhos M, Fareed J. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Semin Thromb Hemost 2008; 34: 7485.
  • 9
    Harenberg J. Overview on guidelines and recommendations for generic low-molecular-weight heparins. Thromb Res 2011; 127 (Suppl. 3): S1004.
  • 10
    Pouplard C, Amiral J, Borg JY, Vissac AM, Delahousse B, Gruel Y. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium. Br J Haematol 1997; 99: 27380.
  • 11
    Mourier PA, Viskov C. Chromatographic analysis and sequencing approach of heparin oligosaccharides using cetyltrimethylammonium dynamically coated stationary phases. Anal Biochem 2004; 332: 299313.
  • 12
    Guerrini M, Elli S, Gaudesi D, Torri G, Casu B, Mourier P, Herman F, Boudier C, Lorenz M, Viskov C. Effects on molecular conformation and anticoagulant activities of 1,6-anhydrosugars at the reducing terminal of antithrombin-binding octasaccharides isolated from low-molecular-weight heparin enoxaparin. J Med Chem 2010; 53: 803040.
  • 13
    Piliarik M, Vaisocherova H, Homola J. Surface plasmon resonance biosensing. Methods Mol Biol 2009; 503: 6588.
  • 14
    Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106: 27105.
  • 15
    Amiral J, Bridey F, Dreyfus M, Vissac A, Fressinaud E, Wolf M, Meyer D. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 956.
  • 16
    Denton J, Lane DA, Thunberg L, Slater AM, Lindhal U. Binding of platelet factor 4 to heparin oligosaccharides. Biochem J 1983; 209: 45560.
  • 17
    Guerrini M, Guglieri S, Casu B, Torri G, Mourier P, Boudier C, Viskov C. Antithrombin-binding octasaccharides and role of extensions of the active pentasaccharide sequence in the specificity and strength of interaction. Evidence for very high affinity induced by an unusual glucuronic acid residue. J Biol Chem 2008; 283: 2666275.
  • 18
    Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost 1995; 74: 88692.
  • 19
    Walenga JM, Jeske WP, Prechel MM, Bacher P, Bakhos M. Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs. Semin Thromb Hemost 2004; 30 (Suppl. 1): 6980.
  • 20
    Alban S, Greinacher A. Role of sulfated polysaccharides in the pathogenesis of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia, 3rd edn. New York, NY, Basel: Marcel Dekker, Inc, 2004: 197221.
  • 21
    Warkentin TE. Fondaparinux: does it cause HIT? Can it treat HIT? Expert Rev Hematol 2010; 3: 56781.